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A B S T R A C T   
Disorders of Sex Development (DSD) are some of the most controversial and challenging conditions that pediatric 
urologists treat. This may be especially true in mosaic 45X/46XY DSD, due to the inability to ascertain in the 
neonatal period which gender identity will best suit a given child with this condition. It has therefore been 
proposed to forgo any irreversible surgical interventions. In order to address the concern of early testosterone 
production in a nonsurgical manner we describe a case in which we treat a patient with a GnRH agonist to block 
the early physiologic rise in testosterone during the neonatal mini-puberty.   
Introduction 
Disorders of sex development (DSD) encompass a spectrum of con-
ditions in which a discrepancy exists between a patient’s chromosomal 
sex, gonadal histology and the appearance of the external genitalia. 
More than a decade after the Chicago consensus, there remains a wide 
disparity in opinion regarding treatment among physicians for nearly 
every category of DSD.1 
In the past, there existed a tendency to assign gender in the newborn 
period and thereafter proceed with surgical intervention in order to 
create an external appearance in keeping with this assigned gender. This 
strategy has largely been supplanted by a strategy to forgo early surgical 
intervention. This results in a number of potential social and physio-
logical dilemmas that require the expertise of a multidisciplinary team. 
Parents and health care professionals justifiably fear that continued 
exposure to elevated testosterone levels during the mini-puberty of in-
fancy could adversely affect the child’s phenotypic appearance (e.g. 
increasing phallic size) and result in further brain imprinting. This may 
be particularly detrimental if the child ultimately declares their gender 
identity to be female. Borrowing from the paradigm of suppressing the 
onset of puberty in transgender children, we describe the successful 
treatment of a newborn with mosaic DSD with a GnRH agonist to block 
the physiologic rise in testosterone during the first 6 months of life. 
Case report 
The multidisciplinary DSD team was asked to consult on a full term 
newborn child for a chief complaint of ambiguous genitalia. The mother 
had received prenatal counseling and had undergone screening with 
cell-free DNA that revealed no identifiable Y chromosomal markers. The 
family had therefore anticipated the female gender. 
Upon delivery, the child was noted to have a two-centimeter phallus 
with a proximal urethral meatus and labioscrotal fusion (Fig. 1). The left 
gonad was initially palpated in the high inguinal location and the right 
gonad could not be appreciated on physical examination. A pelvic ul-
trasound revealed a uterus with failure to identify either gonad. Serum 
testosterone on day 5 of life returned at 16 ng/dl. Karyotype returned as 
45X/46XY and a diagnosis of mosaic DSD was made. A repeat serum 
testosterone obtained one week later revealed that the testosterone level 
had risen. An endoscopic evaluation at 21 days of life revealed a hemi- 
vagina that extended to the right of midline and laparoscopy confirmed 
the presence of a right hemi-uterus and fallopian tube with a streak like 
structure on the right and a left undescended intra-abdominal testicle 
with associated inguinal hernia (Fig. 2a and b). 
Upon being presented with this information the parents demanded 
immediate gonadal removal in order to limit the child’s exposure to 
endogenous androgens. The family was presented with the additional 
option of medically suppressing testosterone during the mini-puberty 
and agreed to the use of a GnRH agonist for this purpose. Treatment 
was initiated with depot Lupron 0.3 mg/kg IM monthly x 2 month. This 
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suppressed testosterone levels to pre-pubertal levels (<2.5 ng/dl). At 
one year of age the right streak gonad was removed, the left hernia 
repaired and the left testicle biopsied and secured in a supra-facial 
location. 
As per the parent’s wishes, the patient continues in the female sex 
assignment. Frequent visits to our multidisciplinary clinic have helped 
to reinforce the value of an observational approach and manage the 
unique stressors that come with having a child with genital ambiguity. 
Discussion 
Patients with DSD may present in a number of different ways. Genital 
ambiguity is commonly the manner in which children are identified. The 
combination of hypospadias with one or bilateral undescended gonads, 
inguinal hernias in a phenotypic female and amenorrhea in a teenager 
are other common ways in which these patients present for medical 
evaluation.2 Prenatally, DSD may be suspected if the results of amnio-
centesis do not correlate with ultrasound images of the genitalia. 
Recently, with the advent of maternal cell-free DNA testing an addi-
tional mode of presentation has emerged. Although one can accurately 
predict the gender of the newborn from the PCR amplification of fetal 
DNA, the prediction of fetal gender can be in error in as many as 4% of 
cases.3 In our patient the family was informed that their child was likely 
female and was subsequently found to have mosaic DSD. This case serves 
to underscore the continued need for caution with this diagnostic 
modality. 
The appearance of a child with mosaic DSD presents as a spectrum 
ranging from phenotypic males with a completely formed male urethra 
and bilaterally descended gonads to phenotypic females with bilateral 
streak gonads (so called Turners syndrome). Patients may also present 
with genitalia that is ambiguous.4 In the past, early gender assignment 
was frequently made based on size of the phallus and levels of measured 
serum testosterone. However, cases in which the patient later identified 
with a gender other than that which was assigned has brought this 
paradigm of management into question. 
In the case presented, our multidisciplinary team explained to the 
family that it is not possible to know the gender identity of a child with 
mosaic DSD. The family, having anticipated a female, chose to raise the 
child in the female gender role. After explaining that their child had a 
rise in testosterone consistent with neonatal mini-pubertal surge, the 
family insisted that the gonads be immediately removed in order to 
minimize additional masculinizing effects. Faced with this dilemma, we 
proposed the use of a GnRH agonist to suppress this rise in postnatal 
testosterone. 
The use of GnRH agonists to suppress testosterone in children has 
precedent. The World Professional Association of Transgender Health’s 
standards of care has recommended suspending puberty by this means in 
certain gender non-conforming minors. By suppressing hormone levels 
it is possible to obviate the development of secondary sexual charac-
teristics that are not in keeping with the individuals chosen gender.5 
We have successfully suppressed testosterone in our patient with 
mosaic DSD with the monthly delivery of depot Lupron. The potential 
advantage of this is clear, minimizing the effect of additional androgens 
on genital appearance without performing irreversible surgery to 
remove the gonads in the neonatal setting. 
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Fig. 1. Appearance of external genitalia at birth.  
Fig. 2a. Laparoscopic appearance of Left Gonad: Testicle.  
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